The results of determining compatibility in the MLC reaction in hemoblastosis patients undergoing bone marrow transplantation from HLA-identical siblings

• Published in: Gematologiia i transfuziologiia Vol. 38; no. 5; p. 17
• Main Authors: Shpakova, A P, Bulycheva, T I, Dronova, V M, Okhrimenko, T N, Liubimova, L S, Mendeleeva, L P, Savchenko, V G
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01-05-1993
• Subjects: Bone Marrow Transplantation - immunology; Female; Genotype; Haplotypes - genetics; Haplotypes - immunology; HLA Antigens - blood; HLA Antigens - genetics; Humans; Immunophenotyping; Leukemia - genetics; Leukemia - immunology; Leukemia - therapy; Lymphocyte Culture Test, Mixed - methods; Lymphocyte Culture Test, Mixed - statistics & numerical data; Male; Transplantation, Homologous
• ISSN: 0234-5730

Compatibility in mixed lymphocyte culture (MLC) test was determined for 60 hemoblastosis patients with their 71 HLA-identical sibs to transplant allogenic syngeneic bone marrow. A protocol for the MLC radioisotope micromethod with culturing in plates is described for the pair donor-recipient in the direct and reverse variants covering about 20 variants of mixed cultures. This secures the results' reliability. Plotting of the MLC compatibility results for each pair has been proposed. Incompatibility by MLC was revealed in 5 out of 71 pairs (7%). Bone marrow transplantation was performed in 30 patients from their HLA-identical/MLC-compatible sibs. The secondary disease due to incompatibility missed in the MLC reaction occurred in 5 cases (16.7%), transplant rejection in 2 cases (6.7%), which is less in number than literature data. It was established that determination of compatibility by MLC may serve a reliable criterion of assessing a genotypic pair HLA identity and should be conducted before each allogenic and syngeneic transplantation of bone marrow. The protocols of the method performance and compatibility parameters evaluation warrant high significance of the compatibility definition confirmed by clinical responses with minimal probability of secondary disease.